31 results
Progression-free Survival  #EBM #Honc #Osimertinib #NSCLC #Survival #NEJM
Progression-free Survival #EBM ... #Honc #Osimertinib ... #NSCLC #Survival
Algorithm for the Evaluation of Anemia #Diagnosis #EM #IM #Honc #Anemia #Differential #Workup #Algorithm #Microcytic #Macrocytic
Algorithm for the ... Anemia #Diagnosis #EM ... #IM #Honc #Anemia ... Differential #Workup #Algorithm
Early Events in Acute GVHD #Pathophys #Honc #GVHD #GraftVersusHostDisease #NEJM
in Acute GVHD #Pathophys ... #Honc #GVHD #GraftVersusHostDisease
Alectinib versus Crizotinib in Untreated ALK-Positive Non–Small-Cell Lung Cancer #EBM #Honc #Alectinib #Crizotinib #ALK #ALKPositive #NSCLC
Non–Small-Cell Lung Cancer #EBM ... #Honc #Alectinib ... #ALKPositive #NSCLC
Possible Mechanisms Underlying Immune-Related Adverse Events #Pathophys #Honc #ImmuneRelatedAdverseEvents #Immunotherapy #NEJM
Adverse Events #Pathophys ... #Honc #ImmuneRelatedAdverseEvents
The Pathway of Heme Synthesis, Showing Pathway Intermediates and End-Product Regulation by Heme #Pathophys #Honc #Heme
Regulation by Heme #Pathophys ... #Honc #Heme #Synthesis
Evaluation of Lymphadenopathy - Localized vs Generalized #Diagnosis #EM #IM #Honc #Lymphadenopathy #Localized #Generalized #Infectious #Malignancy
Generalized #Diagnosis #EM ... #IM #Honc #Lymphadenopathy ... #Differential #Algorithm
Biologic Events Leading to Chronic GVHD #Pathophys #Honc #Pharm #GVHD #GraftVersusHostDisease #Therapeutic #Pathways #NEJM
Chronic GVHD #Pathophys ... #Honc #Pharm #GVHD
Role of G6PD in Protection against Oxidative Damage #Pathophys #Peds #Genetics #Honc #Favism #g6pd #NEJM
Oxidative Damage #Pathophys ... Peds #Genetics #Honc
Durvalumab after Chemoradiotherapy in Stage III Non–Small-Cell Lung Cancer - Progression-free Survival in the Intention-to-Treat Population.
#EBM #Honc #PACIFIC ... #Durvalumab #NSCLC